Sichuan Huiyu Pharmaceutical Co Ltd

SHG:688553 China Drug Manufacturers - Specialty & Generic
Market Cap
$1.03 Billion
CN¥7.53 Billion CNY
Market Cap Rank
#10134 Global
#2185 in China
Share Price
CN¥17.77
Change (1 day)
-1.06%
52-Week Range
CN¥13.59 - CN¥27.61
All Time High
CN¥38.07
About

Sichuan Huiyu Pharmaceutical Co., Ltd. research and develops, produces, and sells anti-tumor injection in China and internationally. The company offers injection drug products, such as pemetrexed disodium, methrotraxate, docetaxel, azacitidine, oxaliplatin, cyclophosphamide, irinotecan hydrochloride, paclitaxel, bendamustine hydrochloride, decitabine, palonosetron hydrochloride, plerixafor, levet… Read more

Sichuan Huiyu Pharmaceutical Co Ltd (688553) - Cash Flow Conversion Efficiency

Latest cash flow conversion efficiency as of September 2025: 0.016x

Based on the latest financial reports, Sichuan Huiyu Pharmaceutical Co Ltd (688553) has a cash flow conversion efficiency ratio of 0.016x as of September 2025.

Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥58.54 Million) by net assets (CN¥3.72 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Sichuan Huiyu Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2017–2024)

This chart illustrates how Sichuan Huiyu Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.

Sichuan Huiyu Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Sichuan Huiyu Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.

Annual Cash Flow Conversion Efficiency for Sichuan Huiyu Pharmaceutical Co Ltd (2017–2024)

The table below shows the annual cash flow conversion efficiency of Sichuan Huiyu Pharmaceutical Co Ltd from 2017 to 2024.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 CN¥3.97 Billion CN¥242.96 Million 0.061x +244.81%
2023-12-31 CN¥3.77 Billion CN¥66.93 Million 0.018x -66.02%
2022-12-31 CN¥3.72 Billion CN¥194.06 Million 0.052x -58.39%
2021-12-31 CN¥3.56 Billion CN¥446.36 Million 0.125x -75.70%
2020-12-31 CN¥751.48 Million CN¥387.95 Million 0.516x -35.33%
2019-12-31 CN¥408.65 Million CN¥326.22 Million 0.798x +193.22%
2018-12-31 CN¥-150.70 Million CN¥129.06 Million -0.856x -1305.63%
2017-12-31 CN¥-185.32 Million CN¥-13.16 Million 0.071x --